Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1990 Aug;30(2):297–300. doi: 10.1111/j.1365-2125.1990.tb03779.x

Changes in indocyanine green kinetics after the administration of enalapril to healthy subjects.

J Geneve 1, T Le Dinh 1, A Brouard 1, M Bails 1, J M Segrestaa 1, C Caulin 1
PMCID: PMC1368232  PMID: 2206792

Abstract

Enalapril maleate, an angiotensin converting enzyme inhibitor, is a vasodilator liable to modify regional blood flow. The effects of an oral dose of 40 mg enalapril maleate on indocyanine green (ICG) kinetics were assessed in nine healthy subjects. At 4 h after the administration of the drug, a 35% decrease in ICG clearance was observed (P less than 0.01) associated with a 23% decrease in its volume of distribution (P less than 0.02). The half-life of ICG was not altered significantly by enalapril. These results suggest that the administration of enalapril maleate to healthy subjects may reduce apparent liver plasma flow and plasma volume, as a consequence of the pooling of blood in the hepatosplanchnic area.

Full text

PDF
300

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ayers C. R., Baker K. M., Weaver B. A., Lehman M. R. Enalapril maleate versus captopril. A comparison of the hormonal and antihypertensive effects. Drugs. 1985;30 (Suppl 1):70–73. doi: 10.2165/00003495-198500301-00010. [DOI] [PubMed] [Google Scholar]
  2. Bosch J., Arroyo V., Betriu A., Mas A., Carrilho F., Rivera F., Navarro-Lopez F., Rodes J. Hepatic hemodynamics and the renin-angiotensin-aldosterone system in cirrhosis. Gastroenterology. 1980 Jan;78(1):92–99. [PubMed] [Google Scholar]
  3. CAESAR J., SHALDON S., CHIANDUSSI L., GUEVARA L., SHERLOCK S. The use of indocyanine green in the measurement of hepatic blood flow and as a test of hepatic function. Clin Sci. 1961 Aug;21:43–57. [PubMed] [Google Scholar]
  4. Creager M. A., Halperin J. L., Bernard D. B., Faxon D. P., Melidossian C. D., Gavras H., Ryan T. J. Acute regional circulatory and renal hemodynamic effects of converting-enzyme inhibition in patients with congestive heart failure. Circulation. 1981 Sep;64(3):483–489. doi: 10.1161/01.cir.64.3.483. [DOI] [PubMed] [Google Scholar]
  5. Crossley I. R., Bihari D., Gimson A. E., Westaby D., Richardson P. J., Williams R. Effects of converting enzyme inhibitor on hepatic blood flow in man. Am J Med. 1984 May 31;76(5B):62–65. doi: 10.1016/0002-9343(84)90886-6. [DOI] [PubMed] [Google Scholar]
  6. Eriksson L. S., Kågedal B., Wahren J. Effects of captopril on hepatic venous pressure and blood flow in patients with liver cirrhosis. Am J Med. 1984 May 31;76(5B):66–70. doi: 10.1016/0002-9343(84)90887-8. [DOI] [PubMed] [Google Scholar]
  7. Gomez H. J., Cirillo V. J., Irvin J. D. Enalapril: a review of human pharmacology. Drugs. 1985;30 (Suppl 1):13–24. doi: 10.2165/00003495-198500301-00004. [DOI] [PubMed] [Google Scholar]
  8. LEEVY C. M., MENDENHALL C. L., LESKO W., HOWARD M. M. Estimation of hepatic blood flow with indocyanine green. J Clin Invest. 1962 May;41:1169–1179. doi: 10.1172/JCI104570. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Leier C. V. Regional blood flow responses to vasodilators and inotropes in congestive heart failure. Am J Cardiol. 1988 Sep 9;62(8):86E–93E. doi: 10.1016/s0002-9149(88)80019-5. [DOI] [PubMed] [Google Scholar]
  10. Matsuki K., Sakata T. Angiotensin-converting enzyme in diseases of the liver. Am J Med. 1982 Oct;73(4):549–551. doi: 10.1016/0002-9343(82)90335-7. [DOI] [PubMed] [Google Scholar]
  11. Millar J. A., Derkx F. H., McLean K., Reid J. L. Pharmacodynamics of converting enzyme inhibition: the cardiovascular, endocrine and autonomic effects of MK421 (enalapril) and MK521. Br J Clin Pharmacol. 1982 Sep;14(3):347–355. doi: 10.1111/j.1365-2125.1982.tb01990.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Moncloa F., Sromovsky J. A., Walker J. F., Davies R. O. Enalapril in hypertension and congestive heart failure. Overall review of efficacy and safety. Drugs. 1985;30 (Suppl 1):82–89. doi: 10.2165/00003495-198500301-00012. [DOI] [PubMed] [Google Scholar]
  13. Rajagopalan B., Raine A. E., Cooper R., Ledingham J. G. Changes in cerebral blood flow in patients with severe congestive cardiac failure before and after captopril treatment. Am J Med. 1984 May 31;76(5B):86–90. doi: 10.1016/0002-9343(84)90891-x. [DOI] [PubMed] [Google Scholar]
  14. Richer C., Thuillez C., Giudicelli J. F. Perindopril, converting enzyme blockade, and peripheral arterial hemodynamics in the healthy volunteer. J Cardiovasc Pharmacol. 1987 Jan;9(1):94–102. [PubMed] [Google Scholar]
  15. Shepherd A. N., Hayes P. C., Jacyna M., Morrison L., Bouchier I. A. The influence of captopril, the nitrates and propranolol on apparent liver blood flow. Br J Clin Pharmacol. 1985 Mar;19(3):393–397. doi: 10.1111/j.1365-2125.1985.tb02659.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Wilkinson G. R., Shand D. G. Commentary: a physiological approach to hepatic drug clearance. Clin Pharmacol Ther. 1975 Oct;18(4):377–390. doi: 10.1002/cpt1975184377. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES